2-Deoxy-D-Glucose: A Novel Pharmacological Agent for Killing Hypoxic Tumor Cells, Oxygen Dependence-Lowering in Covid-19, and Other Pharmacological Activities

Singh, Raman; Gupta, Vidushi; Kumar, Antresh; Singh, Kuldeep

doi:https://doi.org/10.1155/2023/9993386

Advances in Pharmacological and Pharmaceutical Sciences

On this page

Abstract Introduction Conclusions Data Availability Conflicts of Interest Acknowledgments References Copyright Related Articles

Review Article | Open Access

Volume 2023 | Article ID 9993386 | https://doi.org/10.1155/2023/9993386

2-Deoxy-D-Glucose: A Novel Pharmacological Agent for Killing Hypoxic Tumor Cells, Oxygen Dependence-Lowering in Covid-19, and Other Pharmacological Activities

Raman Singh,¹Vidushi Gupta,²Antresh Kumar,³and Kuldeep Singh⁴

Academic Editor: Srinivas Mutalik

Received07 Dec 2022

Revised02 Jan 2023

Accepted17 Feb 2023

Published02 Mar 2023

Abstract

The nonmetabolizable glucose analog 2-deoxy-D-glucose (2-DG) has shown promising pharmacological activities, including inhibition of cancerous cell growth and N-glycosylation. It has been used as a glycolysis inhibitor and as a potential energy restriction mimetic agent, inhibiting pathogen-associated molecular patterns. Radioisotope derivatives of 2-DG have applications as tracers. Recently, 2-DG has been used as an anti-COVID-19 drug to lower the need for supplemental oxygen. In the present review, various pharmaceutical properties of 2-DG are discussed.

1. Introduction

2-Deoxy-D-glucose (2-DG, 2-deoxy-D-arabino-hexopyranose) is a natural [1], nonmetabolizable glucose analog and a competitive inhibitor of glycolysis [2] in which the 2-hydroxyl group is replaced by hydrogen (Figure 1). 2-DG blocks the activity of different enzymes involved in glycolysis, leading to cell death. Hyperglycemic condition aggravates cancer cell proliferation, inflammatory conditions, and viral infection [3]. In this review, the pharmaceutical properties of 2-DG have been discussed. This review article describes the pharmacological properties specific to 2-DG and its isotopic derivatives but excludes substituted derivatives of 2-DG.

1.1. Drug-likeness of 2-DG

2-DG has a molecular weight of 164.158 Da, logP of −1.525, five hydrogen bond acceptors (HBA), and four hydrogen bond donors (HBD). Thus, there are four matching Lipinski’s rules. The polar surface area (PSA) of 2-DG was 90.15, and it consisted of one rotatable bond (RotB). Thus, two matching Veber’s rules exist.

1.2. Toxicity of 2-DG

Toxic effects of 2-DG result from its ability to block glycosylation [4, 5] but not glycolysis [6]. Ketogenic Diet increases tolerance against glycolysis inhibitors [7]. Experimental results show that 2-DG is a relatively harmless compound at low doses, but that it can lower blood pressure and slow breathing at higher doses [8]. Most of the studies indicate that a clinically tolerable dose of 2-DG is up to 63 mg/kg/day [9]. Beyond this several side effects are observed including reversible hyperglycemia, gastrointestinal bleeding, and QTc prolongation [9]. However, recent studies carried out by DRDO use a higher dose of 90 mg/kg/day [10]. Exposure to 2-DG causes cytotoxicity and radiosensitization via a mechanism involving changes in thiol metabolism and these effects may be more prominent in transformed vs. normal cells [11].

2. Analytical Methods for Detection and Determination of 2-Deoxy-D-Glucose

The concentration and purity can be measured in a sample of crystalline or liquid material by HPLC with accuracy and precision suitable for the analysis of active pharmaceutical ingredients and drug products [12]. The method is suitable for the standardization and quality control of APIs and drugs [12]. UV-HPLC (195 nm) has been used to detect and quantify 2-DG using a μBondapak 10 μm NH₂ column and a Varian MicroPak 10 μm NH₂ column. The retention time is usually four minutes with an eluent 85% MeCN/H₂O [13]. Polymer-based amino column (HILICpak VG-50 4E column) and Shodex SUGAR SC1011 columns have also been used to separate 2-DG and glucose. Pharmacokinetic studies of 2-DG involve the estimation of 2-deoxyglucose in the plasma [14]. For this purpose, precolumn fluorescent derivatization was achieved by reductive amination of 2-DG using sodium cyanoborohydride and 2-aminobenzoic acid [14].

3. Pharmaceutical Profile of 2-DG

The molecule 2-DG follows Lipinski’s rule of five and has several activities, kills hypoxic tumor cells, and lowers oxygen dependency in case of Covid-19 (Figure 2). A number of studies have described different biological activities [3], but it is not approved as a drug until May 2021 [15]. In May 2021, 2-DG was found an emergency use as an anti-Covid-19 drug allowing patients to recuperate more quickly by lowering the need for supplemental oxygen. 2-Deoxyglucose (2-DG) is a toxic glucose analog. 2-DG has a pleiotropic mechanism of action (Figure 3) [16–18].

3.1. Inhibition of N-Linked Glycosylation Process

2-DG also contains a structural resemblance to mannose, which strongly interferes in the N-linked glycosylation process, which resulted in to halt in protein synthesis and causes ER stress. As D-glucose and D-mannose are epimers at C-2, the deoxygenation at C-2 gives one identical product, i.e., 2-DG (Figure 4). Therefore, 2-DG affects D-mannose metabolism, including glycosylation processes [16], and induces endoplasmic reticulum stress [16, 19]. 2-DG stimulates autophagy, enhances oxidative stress, and suppresses N-linked glycosylation [20].

2-DG mimics mannose has brought up the prospect of developing it as an antiviral agent, in addition to restricting cancer growth [21]. Glycolytic inhibitors such as 2-DG potentiate the activity of Paclitaxel [22].

3.2. Inhibition of Inflammation

Recent reports suggest the usefulness of 2-deoxy-D-glucose in the inhibition of inflammation [23], controlling respiratory infections, and treatment of human genital herpes [24]. 2-DG shows anti-inflammatory activities through the regulation of anti-inflammatory mediators and the polarization of macrophages [3]. During ocular infection with herpes simplex virus (HSV), stromal keratitis occurs due to inflammatory reactions in the eye. In vivo experiments to limit glucose utilization using 2-DG showed diminished lesions with fewer proinflammatory effectors [25]. 2-DG also acts as a potential energy restriction mimetic agent (ERMA) [26], and has application in reducing acute inflammation events caused by pathogen-associated molecular patterns (PAMPs) [26], 2-DG application as ERMA in drinking water can help to avoid pathogenic exposure-induced inflammatory events, which can help to prevent both acute and chronic inflammatory illnesses [26]. In the mice model, treatment with 2-DG (0.4% w/v in drinking water) reduces infiltration of inflammatory cells, inflammatory signaling activation, oxidative stress, capillary damage in lungs [26], and reduced the BALF and serum [26]. 2-DG reduces the inflammatory responses triggered by glycogen accumulation caused by coal dust because macrophages have reconstituted glycogen metabolism [27]. A study on dextran sulfate sodium-induced colitis-mouse (mouse model for inflammatory bowel disease), alleviated laminarin-induced arthritis in the SKG mouse (model for human rheumatoid arthritis), LPS shock (model for a cytokine storm), and LPS-induced pulmonary inflammation (model for COVID-19) suggested that 2-DG is effective for the treatment of various inflammatory disease due to its capability to inhibit cytokine receptor glycosylation [28].

3.3. Hypoxic Suppressor of Cancer Cell Growth

It is well documented that cancer cells utilize more energy than normal cells, and they favor glycolysis for ATP production and cell metabolism. Utilization of glycolytic energy by tumor cells even in the presence of oxygen is called aerobic glycolysis or the Warburg effect. This glucose metabolism in tumor cells showed a promising target for the regulation of the growth of cancerous cells. 2-DG competes with the binding of glucose to hexokinase (HK), which converts into 2-DG-6-phosphate (2-DG-6-P) by phosphorylation. The accumulation of 2-DG-6-P in cells inhibits phosphoglucose isomerase (PGI) activity. Thus, 2-DG limits glucose uptake and the downstream metabolic pathway, which depletes the ATP level and induces cell death.

Several applications of 2-DG are known for the efficient elimination of cancer cells, and the synergetic effect of 2-DG has been reported in the literature [29]. The limited therapeutic effect of 2-DG in cancer treatment is overcome by its beneficial synergistic anticancer effect with other therapeutic agents or radiotherapy [20] by blocking glycolysis in hypoxic tumor cells and subsequent cell death [30]. 2-DG manipulates its similarity to glucose and the tendency of cancer cells to utilize glycolysis even in the presence of oxygen, a process known as aerobic glycolysis or the Warburg effect [31, 32]. 2-DG acts as a D-glucose mimic, suppressing glycolysis by forming and accumulating 2-deoxy-D-glucose-6-phosphate (2-DG6P) inside cells, blocking hexokinase and glucose-6-phosphate isomerase, and causing cell death (Figure 2) [33].

Nanoparticles or nanosized molecules show the pharmaceutical effect differently. Nanoliposomes have been used in various drug delivery systems. 2-DG-containing nanoliposomes have shown inhibition of glycolysis in cancer cells. The synergistic effect of these 2-DG-loaded liposomes with the coloaded drug enhances mitochondrial depolarization and subsequent apoptosis [34].

Studies have shown that 2-Fluoro-Deoxyglucose resembles glucose more closely than 2-DG. Lampidis employed a QSAR-like method combined with a flexible coupling strategy to determine that the analog binding affinities to hexokinase I decrease as the size of the halogen increases [30].

2-fluoro-2-deoxy-D-glucose (2-FG) >2-chloro-2-deoxy-D-glucose (2-CG) > 2-bromo-2-deoxy-D-glucose (2-BG).

D-glucose had the highest affinity binding affinity to hexokinase I, followed by 2-FG and 2-DG [30]. 2-DG dramatically increased ATP depletion and 4E-BP1 phosphorylation. On the other hand, high amounts of 2-FDG can prevent further protein glycosylation processes by competing with glucose [35].

When the energy supplied to the cell decreases, 2-DG causes metabolic stress, which inhibits immune cells' (leucocytes) actions and causes downregulation of immune-relevant genes (CSF-1R, NCCRP-1, Hep, TCR-a, IgMH, MHC-II, C3, and IL-1). [36] On DU145 cells and mouse xenograft tumors, 2-DG combined with buforin IIb causes greater inhibition of proliferation, higher arrest of the G1 cell cycle, and more apoptosis than either treatment alone [37].

Several drugs have been tested in combination with 2-DG to inhibit the growth of cancer cells. These drugs and corresponding cancer types are listed in Table 1.

3.4. Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Autosomal dominant polycystic kidney disease (ADPKD) is characterized by defective glucose metabolism. Chiaravalli studied the effect of low doses of 2-DG on ADPKD progression in orthologous and slowly progressive murine models created postnatally by inducible inactivation of the Pkd1 gene. These studies established proof-of-principle support for the use of 2-DG as a therapeutic strategy in ADPKD [72]. 2-DG can suppress the activity of seizures and retards the epilepsy progression in vitro as well as in vivo [73].

The combination of metformin and a low dose of 2-deoxyglucose synergically inhibits cyst formation and human polycystic kidney cell proliferation [74, 75]. Cheong and his colleagues reported that 2-DG with metformin can prevent tumor growth in mouse xenograft models [76].

Due to its similarity in the structure of glucose and nonparticipation in glycolysis [77], 2-DG has emerged as a tool for metabolism-independent GS investigations [78, 79]. Studies on the effect of 2-DG treatment on the mHypoE-29/1 cell line suggest that the metabolism-dependent GS pathway is responsible for glucose detection in neuronal cells and the downregulation of AgRP mRNA levels.

The effect of exposure to 2-DG on AgRP mRNA levels in the adult mHypoA-NPY/GFP model and the embryonic model showed that both cell lines expressed Tas1R2 and Tas1R3 mRNA transcripts, indicating the involvement of metabolism-independent glucose sensing mechanisms. These studies also suggest that control of AgRP mRNA expression in embryonic cells is metabolism-dependent, whereas adult cells may act in a metabolism-independent manner [80].

2-DG is an antagonist of glucose metabolism and targets hypoxic cancer cells resistant to chemotherapy by induction of apoptosis [81], 2-DG inhibits angiogenesis [82], and 2-DG inhibits metabolism [21].

2-DG inhibits T-cell-mediated cytolysis since 2-DG metabolites compete with glucose metabolites for key enzymes (such as glycosyltransferases) that are necessary for cytolysis expression [83].

The synthesis and characterization of CyNE 2-DG, a new NIR fluorescent DG analog, was reported by Vendrell et al. The coupling of 2-deoxy-glucosamine and tricarbocyanine carboxylic acid in the presence of the coupling reagent, i.e., HATU results in the formation of CyNE 2-DG [84].

Immobilization and 2-DG-induced central neuroglycopenia should be identified as different types of stressful stimuli, causing their effects through different neural pathways, based on secretory, hemodynamic, and synthesis of adrenal catecholamine rate responses [85].

The suppression of proteoglycan production by the GAG chain could be linked to ATP depletion in cells. In confluent primate VSMCs, the ATP content of cells decreased by 25–30% after exposure to 2-deoxyglucose. ATP levels and proteoglycan synthesis recovered to baseline after 2-DG was removed [86]. 2-DG inhibits substance P (SP) production in the bodies of sensory ganglion cells of vagal cells, as well as its bidirectional transit to the CNS, thoracic, and abdominal viscera [87]. Total protein synthesis was not affected when the ratio of hexose to 2-DG was 20 1 or greater. Under similar conditions, invertase and acid phosphatase production and secretion are inhibited by 2-DG. Glucan formation was also inhibited. The mechanism of inhibition of total uptake of external sugar by 2-DG after a lag period involves intracellular 2-DG-6-P, which directly inhibits the conversion of fructose-6-P to glucose-6-P and mannose-6-P by phosphohexose isomerases; simultaneously decreasing the transport of fructose or maltose into cells [88–90].

2-DG inhibits cellular repair phenomena, even after completing the unscheduled DNA synthesis [91–94]. 2-DG inhibits DNA repair and the repair of potentially lethal damage in cancerous cells. These two phenomena were studied in respiratory-deficient yeast cells irradiated with X assayed by unscheduled DNA synthesis and cell viability after irradiation, respectively [92–94].

LPS-induced aerobic glycolysis is inhibited by 2-DG; therefore, collagen synthesis is also inhibited [95]. Glycolysis suppression results in decreased muscle protein synthesis as a result of decreased basal mTORC1 signaling [96].

3.5. Antiseizure Effects and Retarding Effect in Epilepsy Progression

2-DG exhibits antiseizure effects through the netrin-G1-KATP signaling pathway by upregulating K (ATP) subunits kir6.1 and kir6.2 [97, 98]. In animal models, it retards the progression of epilepsy [99]. The epileptic brain shows dynamic metabolic changes. Focal zones of onset of seizures are hypometabolic during the interictal period and hypermetabolic during seizures [100]. Therefore, glycolysis plays an important role in these dynamic metabolic changes; therefore, 2-DG could abrogate seizure activity and retard epilepsy progression.

3.6. COVID-19 and 2-DG

Perris hypothesized the use of modified sugars for the treatment of viral infections in 2007 [101]. Later it was found that 2-DG inhibits the propagation of epidemic diarrhea virus [102] in human rhinoviruses [103], pandemic SARS-CoV-2 [103, 104], and endemic human coronaviruses [103]. These in vitro studies suggested broad-spectrum antiviral use of 2-DG [103]. 2-DG limits viral proliferation in the body by selectively killing cells infected with the SARS-CoV-2 virus by halting energy production and viral synthesis [104]. 2-DG has limited use in SARS-CoV-2 patients suffering from stroke, hypoxic-ischemic encephalopathy, and other critical illnesses [105–107]. In Phase II clinical trials, the addition of 90 mg/kg/day of 2-DG to the standard of care (SOC) for the treatment of moderate to severe COVID-19 demonstrated clinical benefit over SOC alone [107].

The Drugs Controller General of India (DCGI) has approved the emergency use of 2-deoxy-D-glucose (2-DG, 1) on 1 May 2021 [15]. 2-DG is used as an adjunct therapy in patients with mild to serious COVID-19 to recover quickly by reducing the supplemental oxygen requirement.

3.6.1. Docking and Computational Studies

COVID-19 disease has emerged as an epidemic of the 21st century due to the nonavailability of effective antiviral agents, as well as its pathophysiology [108]. The fragment molecular orbital (FMO) method has been used to characterize SARS-CoV-2 S-protein binding interactions with the ACE2 and B38 Fab antibodies involved in ACE2-inhibitory binding. These studies helped to understand the amino acid residues critical for molecular recognition between the S-protein and the ACE2 or B38 Fab antibody [109]. The binding of 2-DG and 1,3,4,6-tetra-O-acetyl-2-deoxy-D-glucose to viral main protease 3CLpro and NSP15 endoribonuclease is studied using molecular coupling techniques. These studies show that viral receptors are inactivated due to the formation of a hydrogen bond between 2-DG and proline residues. Furthermore, 1,3,4,6-Tetra-O-acetyl-2-deoxy-D-glucose forms a hydrogen bond with the glutamine amino acid residues of the viral spike glycoprotein [110]. The coronavirus disease 2019 (COVID-19) pandemic has highlighted the value of FDG-PET/CT in diagnosis [111, 112]. Molecular coupling and molecular dynamics simulations showed that 2-DG had a positive interaction with SARS-CoV NSP12 and the SARS-CoV-2 RBD spike-ACE2 complex [113].

Drug-drug interactions (DDI) and synergistic regulatory potential have been investigated in a report describing a molecular coupling and simultaneous molecular dynamics simulation of multiligands to study the combined effect of 2-DG with other 62 selected drugs and phytochemicals. In terms of binding energy, the combination of 2-DG with Ruxolitinib, Telmisartan, and Punicalagin was superior to that of the selected individual compound [114].

3.6.2. Similarity between the Pathophysiology of Cancer Cells and SARS-CoV-2 Infected Cells with Respect to Glycolysis Inhibitors

Cancer cells and virus-infected cells have similarities; both require a large amount of energy because of their very high proliferation rate. This high energy requirement increases glucose uptake by infected cells and uses glycolysis and glycosylation for energy production [115]. It promotes mitochondrial signaling, i.e. aerobic glycolysis. Hyperglycemic conditions, such as diabetes, facilitate the invasion and propagation of SARS-CoV-2 and an aggravated immune response [116, 117]. Thus, impaired glucose metabolism will destroy infected cells and viruses in parallel with cancerous cells. Infected cells hungry for energy will absorb a high amount of glucose antimetabolite compared to normal cells. These facts became the basis of the use of 2-DG in the treatment of COVID-19 [106, 118].

3.6.3. Upregulation of Glycolysis Results in Mortality in COVID-19

COVID-19 is a serious acute respiratory disease associated with cardiovascular complications. The interaction of virus Nsp6 with host proteins from the MGA/MAX complex (MGA, PCGF6, and TFDP1) was studied by expressing the SARS-CoV-2 protein in the hearts of Drosophila and using transcriptomic data. This interaction blocks the antagonistic MGA/MAX complex, which shifts the balance to MYC/MAX and activates glycolysis. Nsp6-mediated upregulation of glycolysis disrupts cardiac mitochondrial function, which increases ROS in heart failure. This could explain the cardiac pathology associated with COVID-19. Inhibition of glycolysis with 2-deoxy-D-glucose reduces the Nsp6-induced cardiac phenotype in flies and mice. These findings suggest glycolysis as a pharmacological target for COVID-19-related heart failure [119].

Thirumalaisamy reported Hyaluronic acid-2-DG conjugated as a novel drug in the treatment of COVID-19 [120]. Replication of SARS-CoV-2 in Caco-2 cells was prevented by inhibiting glycolysis and nontoxic 2-DG concentrations [121]. SARS-CoV-2 replication requires high energy and is supported in colon cancer cells by increased carbon metabolism. Thus, glycolysis inhibitor 2-DG inhibits SARS-CoV-2 replication [121].

3.7. Resistance to 2-DG

Overexpression of the odr1 gene of Schizosaccharomyces pombe produces a strong resistance to 2-DG with different resistance mechanisms for budding yeast and fission yeast [122]. S. pombe Odr1 hydrolase can act in the toxic form of 2-DG, similar to Saccharomyces cerevisiae Dog1/Dog2, which encodes HAD-like hydrolase enzymes and exhibits specific 2-DG-6- phosphatase activity [122].

3.8. Other Applications

The use of 2-DG with low-dose radiation therapy is also suggested for anticancer, anti-inflammatory, and antibacterial/antiviral effects [123]. 2-DG is also used as a hypoglycemic stimulus [66]. 2-DG has been used to assess glucose uptake activity by measuring the intracellular accumulation of 2-DG [124]. [¹⁴C]-deoxyglucose ([¹⁴C]-2-DG) is used as a glucose tracer. The method has been used to trace the exchange of glucose between plasma and brain and its phosphorylation during hexokinase glycolysis in tissues [125]. Direct evaluation of local cerebral metabolic activity is possible by using [¹⁴C]-2-DG in the quantitative autoradiographic method. This method provides access to quantitative measurement of glucose utilization and histological identification of affected cortical areas [126].

PET is used to measure glucose metabolism using the 2-DG method proposed by Sokoloff et al. Similarly to 2-DG, F18-labeled deoxyglucose is also an analog of glucose and is taken up in the brain and is phosphorylated in glycolysis. The absence of a C-2 hydroxyl prevents glycolysis; thus, it builds up intracellularly.

PET measures arterial tracer concentration, glucose uptake kinetics, and the regional cerebral glucose metabolic rate (rCMRGlc) can be measured or calculated. Positron computed tomography (PCT) and (F-18)2-fluoro-2-deoxy-D-glucose (FDG) are used to measure the local cerebral metabolic rate of glucose [127, 128]. The PCT method is used to measure glucose uptake in breast cancer cells [129]. The method is also used for the study of brain cells [130], lung cells [131], upper airway inflammation [132], infection in the case of multiple ventriculoperitoneal shunts [133], and myocarditis-STREAM [134].

18F-fluoro-2-deoxy-D-glucose has been used in positron emission tomography (FDG-PET) with computed tomography (CT) for lymph node (LN) staging in urothelial carcinoma (UC) [135], follicular lymphoma [136], polymyalgia rheumatica [137], thyroid nodules [138], and detection of bone marrow metastases [139, 140].

4. Synthetic Methods

The synthesis of 2-DG has been described and reviewed in the literature [141–144]. Selected recent methodologies have been discussed here. As D-glucose and D-mannose are epimers in C-2, deoxygenation in C-2 gives an identical product, i.e., 2-DG (Figure 4) [145].

Glucal is the glycal formed from glucose and is one of the common starting materials for the synthesis of 2-DG. A general conversion involves the bromination (or halogenation) of Glycal at C-2 followed by the replacement of bromine with hydrogen. Bromination takes place in nucleophilic solvent using molecular bromine. Binkley et al. reported photolysis of α and β anomers of 7 to yield α and β anomers of 8. Treatment of 8 with Baker ANGA-542 ion exchange resin in methanol produced 2-DG with a yield of 78% yield [141]. Compound 7 was synthesized by nucleophilic bromination of 4 followed by hydrolysis and acetylation (Figure 5) [141].

Masuda and coworkers reported the synthesis of 2-DG from D-glucose. 2-Deoxy-D-glucose was prepared in three steps from natural D-glucose dispensing with any protection/deprotection procedure and was obtained in 48% yield (Figure 6) [146].

Roush and coworkers synthesized 2-DG by ozonolysis of tetrols 12. Tetrols 12 was generated by methanolysis of the corresponding tetraacetates (Figure 7) [147].

Sowden and his coworkers reported the synthesis of D-arabo-2-desoxyhexose from ribose 13 (Figure 8) [148].

2-DG was produced in 95% yield by using a multistep procedure using Rabbit muscle aldolase (RAMA, D-fructose-1,6-diphosphate aldolase). RAMA catalyzed the reaction of 1,3-dioxane-2-acetaldehyde with DHAP followed by dephosphorylation with AP producing a ketone. The NaHB(OAC)₃ mediated reduction of the ketone gave a mixture of diastereomers in a 2 : 1 ratio in 75% yield. The 5S isomer was resolved to give acetal in 55% yield. The deprotection of the acetal with aqueous 1.0M HCI/THF (1 : 1) yielded 2-deoxy-D-arabino-hexose (95%) [149]. Kim and coworkers (Figure 9) synthesized alkyl α-D-2-deoxyglucosides (A2DGs) by using Aspergillus niger α-glucosidase (ANGase) [150].

5. Future Perspectives

2-DG has been investigated for combination therapy to inhibit cancerous cells. However, the recent use of 2-DG to treat COVID-19 patients under emergency conditions has opened up new hope for the development of new antiviral medicines. COVID-19 is a viral disease caused by SARS-CoV-2 variants. Mutation in the virus is of much concern, which results in the deactivation of available drugs and monoclonal vaccines. Thus, a target that is not directly affected via mutation has its own value. Targeting glycolysis in energy-hungry infected cells will stop the multiplication of the virus [117, 119, 151]. Further, all variants of SARS-CoV-2 follow rewired glycolysis, which makes 2-DG as a good starting point for the development of broad-spectrum antiviral [103]. Normal cells could rely on the citric acid cycle and oxidative phosphorylation using Acetyl-CoA from Fatty acids and ketone bodies. The application of 2-DG is dose-dependent, thus safe doses should be determined by their effects.

6. Conclusions

2-DG is a dual D-glucose and D-mannose mimetic and exploits increased glucose metabolism to kill glycolytic cells. The biological effects of the molecule 2-DG include inhibition of sugar uptake, inhibition of glucose metabolism, antiviral, anti-inflammatory, anticancer, antiepileptic activity, and more. It has found use as a tracer, cancer diagnostic tool, and metabolite inhibitor. Positron emission tomography has made use of 18F-fluoro-2-deoxy-D-glucose. Due to its ability to reduce inflammation and kill glycolytic cells, 2-DG exhibits activity against SARS-CoV-2. Antiviral properties of 2-DG have paved the way for the development of new antiviral drugs and therapies for hyperglycemic patients. Further investigation is necessary to determine the safest doses for various applications, the mechanism of action, the toxicity, and the interactions of 2-DG with various edibles.

Data Availability

Data sharing is not applicable to this article.

Conflicts of Interest

The authors declare no conflicts of interest.

Acknowledgments

The authors acknowledge infrastructural support from their respective institutions.

References

T. Murakami, N. Tanaka, T. Tezuka, and C. Chen, “Chemische unterschungen der Inhaltsstoffe von Pteris inaequalis baker var. aequata (miq) tagawa,” Chemical & Pharmaceutical Bulletin, vol. 23, no. 7, pp. 1634–1637, 1975.
View at: Publisher Site | Google Scholar
G. Zhu, N. Guo, Y. Yong, Y. Xiong, and Q. Tong, “Effect of 2-deoxy-d-glucose on gellan gum biosynthesis by Sphingomonas paucimobilis,” Bioprocess and Biosystems Engineering, vol. 42, no. 5, pp. 897–900, 2019.
View at: Publisher Site | Google Scholar
S. Dey, N. Murmu, T. Mondal et al., “Multifaceted entrancing role of glucose and its analogue, 2-deoxy-D-glucose in cancer cell proliferation, inflammation, and virus infection,” Biomedicine & Pharmacotherapy, vol. 156, Article ID 113801, 2022.
View at: Publisher Site | Google Scholar
F. Bost, A.-G. Decoux-Poullot, J. F. Tanti, and S. Clavel, “Energy disruptors: rising stars in anticancer therapy?” Oncogenesis, vol. 5, no. 1, p. e188, 2016.
View at: Publisher Site | Google Scholar
J. Repas, M. Zupin, M. Vodlan et al., “Dual effect of combined metformin and 2-deoxy-D-glucose treatment on mitochondrial biogenesis and PD-L1 expression in triple-negative breast cancer cells,” Cancers, vol. 14, no. 5, 2022.
View at: Publisher Site | Google Scholar
M. Kurtoglu, J. C. Maher, and T. J. Lampidis, “Differential toxic mechanisms of 2-deoxy-D-glucose versus 2-fluorodeoxy-D -glucose in hypoxic and normoxic tumor cells,” Antioxidants and Redox Signaling, vol. 9, no. 9, pp. 1383–1390, 2007.
View at: Publisher Site | Google Scholar
M. Voss, N. Lorenz, A.-L. Luger, J. Steinbach, J. Rieger, and M. Ronellenfitsch, “Rescue of 2-deoxyglucose side effects by ketogenic diet,” International Journal of Molecular Sciences, vol. 19, no. 8, p. 2462, 2018.
View at: Publisher Site | Google Scholar
R. Vijayaraghavan, D. Kumar, S. N. Dube et al., “Acute toxicity and cardio-respiratory effects of 2-deoxy-D-glucose: a promising radio sensitiser,” Biomedical and Environmental Sciences, vol. 19, no. 2, pp. 96–103, 2006.
View at: Google Scholar
L. E. Raez, K. Papadopoulos, A. D. Ricart et al., “A phase i dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors,” Cancer Chemotherapy and Pharmacology, vol. 71, no. 2, pp. 523–530, 2013.
View at: Publisher Site | Google Scholar
R. Pal, G. Naik, V. Rathore, K. Sahu, and R. Kumar, “Comparison between two different successful approaches to COVID-19 pandemic in India (Dharavi versus Kerala),” Journal of Family Medicine and Primary Care, vol. 9, no. 12, p. 5827, 2020.
View at: Publisher Site | Google Scholar
X. Lin, F. Zhang, C. M. Bradbury et al., “2-Deoxy-D-glucose-induced cytotoxicity and radiosensitization in tumor cells is mediated via disruptions in thiol metabolism,” Cancer Research, vol. 63, no. 12, pp. 3413–3417, 2003.
View at: Google Scholar
M. Li, Analytical Methods for Polynuclear, Intech Open, London, UK, 2005.
D. E. Hughes, “Determination of α-2-deoxy-d-glucose in topical formulations by high-performance liquid chromatography with ultraviolet detection,” Journal of Chromatography A, vol. 331, pp. 183–186, 1985.
View at: Publisher Site | Google Scholar
M. K. Gounder, H. Lin, M. Stein et al., “A validated bioanalytical HPLC method for pharmacokinetic evaluation of 2-deoxyglucose in human plasma,” Biomedical Chromatography, vol. 26, no. 5, pp. 650–654, 2012.
View at: Publisher Site | Google Scholar
I. Aiestaran-Zelaia, M. J. Sánchez-Guisado, M. Villar-Fernandez et al., “2 deoxy-D-glucose augments the mitochondrial respiratory chain in heart,” Scientific Reports, vol. 12, no. 1, 6890 pages, 2022.
View at: Publisher Site | Google Scholar
I. Fokt, S. Skora, C. Conrad, T. Madden, M. Emmett, and W. Priebe, “d-Glucose and d-mannose-based metabolic probes. Part 3: synthesis of specifically deuterated d-glucose, d-mannose, and 2-deoxy-d-glucose,” Carbohydrate Research, vol. 368, pp. 111–119, 2013.
View at: Publisher Site | Google Scholar
A. S. Budikhina and M. V. Pashenkov, “The role of glycolysis in immune response,” Immunologiya, vol. 42, no. 1, pp. 5–20, 2021.
View at: Publisher Site | Google Scholar
R. J. Reiter, R. Sharma, and S. Rosales-Corral, “Anti-warburg effect of melatonin: a proposed mechanism to explain its inhibition of multiple diseases,” International Journal of Molecular Sciences, vol. 22, no. 2, p. 764, 2021.
View at: Publisher Site | Google Scholar
J. Zhang, J. Yang, C. Lin et al., “Endoplasmic Reticulum stress-dependent expression of ERO1L promotes aerobic glycolysis in Pancreatic Cancer,” Theranostics, vol. 10, no. 18, pp. 8400–8414, 2020.
View at: Publisher Site | Google Scholar
D. Zhang, J. Li, F. Wang, J. Hu, S. Wang, and Y. Sun, “2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy,” Cancer Letters, vol. 355, no. 2, pp. 176–183, 2014.
View at: Publisher Site | Google Scholar
H. Xi, M. Kurtoglu, and T. J. Lampidis, “The wonders of 2-deoxy-d-glucose,” IUBMB Life, vol. 66, no. 2, pp. 110–121, 2014.
View at: Publisher Site | Google Scholar
A. Cunha, A. C. Rocha, F. Barbosa et al., “Glycolytic inhibitors potentiated the activity of paclitaxel and their nanoencapsulation increased their delivery in a lung cancer model,” Pharmaceutics, vol. 14, no. 10, 2021.
View at: Publisher Site | Google Scholar
R. Francis, P. K. Singh, S. Singh, S. Giri, and A. Kumar, “Glycolytic inhibitor 2-deoxyglucose suppresses inflammatory response in innate immune cells and experimental staphylococcal endophthalmitis,” Experimental Eye Research, vol. 197, Article ID 108079, 2020.
View at: Publisher Site | Google Scholar
H. A. Blough, “2-deoxy glucose as an antiviral agent against herpes simplex,” 1979, US4315001A.
View at: Google Scholar
S. K. Varanasi, D. Donohoe, U. Jaggi, and B. T. Rouse, “Manipulating glucose metabolism during different stages of viral pathogenesis can have either detrimental or beneficial effects,” Journal of Immunology, vol. 199, no. 5, pp. 1748–1761, 2017.
View at: Publisher Site | Google Scholar
S. Pandey, V. Anang, S. Singh, A. N. Bhatt, K. Natarajan, and B. S. Dwarakanath, “2-deoxy-D-Glucose-(2-DG) prevents pathogen driven acute inflammation and associated toxicity,” Innovation in Aging, vol. 4, p. 885, 2020.
View at: Publisher Site | Google Scholar
W. Wang, M. Mu, Y. Zou et al., “Glycogen metabolism reprogramming promotes inflammation in coal dust-exposed lung,” Ecotoxicology and Environmental Safety, vol. 242, Article ID 113913, 2022.
View at: Publisher Site | Google Scholar
I. Uehara, M. Kajita, A. Tanimura et al., “2-Deoxy-d-glucose induces deglycosylation of proinflammatory cytokine receptors and strongly reduces immunological responses in mouse models of inflammation,” Pharmacology Research & Perspectives, vol. 10, no. 2, 2022.
View at: Publisher Site | Google Scholar
R. Yamaguchi, E. Janssen, G. Perkins, M. Ellisman, S. Kitada, and J. C. Reed, “Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy,” PLoS One, vol. 6, no. 9, Article ID e24102, 2011.
View at: Publisher Site | Google Scholar
T. J. Lampidis, M. Kurtoglu, J. C. Maher et al., “Efficacy of 2-halogen substituted d-glucose analogs in blocking glycolysis and killing ‘hypoxic tumor cells,” Cancer Chemotherapy and Pharmacology, vol. 58, no. 6, pp. 725–734, 2006.
View at: Publisher Site | Google Scholar
O. Warburg and S. Minami, “Versuche an überlebendem carcinom-gewebe,” Klinische Wochenschrift, vol. 2, no. 17, pp. 776-777, 1923.
View at: Publisher Site | Google Scholar
R. A. Gatenby and R. J. Gillies, “Why do cancers have high aerobic glycolysis?” Nature Reviews Cancer, vol. 4, no. 11, pp. 891–899, 2004.
View at: Publisher Site | Google Scholar
B. Pajak, E. Siwiak, M. Sołtyka et al., “2-Deoxy-d-Glucose and its analogs: from diagnostic to therapeutic agents,” International Journal of Molecular Sciences, vol. 21, no. 1, p. 234, 2019.
View at: Publisher Site | Google Scholar
B. Yang, Y. Chen, and J. Shi, “Tumor-specific chemotherapy by nanomedicine-enabled differential stress sensitization,” Angewandte Chemie International Edition, vol. 59, no. 24, pp. 9693–9701, 2020.
View at: Publisher Site | Google Scholar
T. W. Gardner, S. F. Abcouwer, M. K. Losiewicz, and P. E. Fort, “Phosphatase control of 4E-BP1 phosphorylation state is central for glycolytic regulation of retinal protein synthesis,” American Journal of Physiology. Endocrinology and Metabolism, vol. 309, no. 6, pp. E546–E556, 2015.
View at: Publisher Site | Google Scholar
F. A. Guardiola, R. Cerezuela, J. Meseguer, and M. A. Esteban, “Effects of 2-deoxy-d-glucose on the immune system of seabream (Sparus aurata L.),” Fish & Shellfish Immunology, vol. 30, no. 2, pp. 592–599, 2011.
View at: Publisher Site | Google Scholar
Y. Wanyan, X. Xu, K. Liu et al., “2-Deoxy-d-glucose promotes buforin IIb-induced cytotoxicity in prostate cancer DU145 cells and xenograft tumors,” Molecules, vol. 25, no. 23, 5778 pages, 2020.
View at: Publisher Site | Google Scholar
M. Bizjak, P. Malavašič, K. Dolinar, J. Pohar, S. Pirkmajer, and M. Pavlin, “Combined treatment with Metformin and 2-deoxy glucose induces detachment of viable MDA-MB-231 breast cancer cells in vitro,” Scientific Reports, vol. 7, no. 1, 2017.
View at: Publisher Site | Google Scholar
C. Bi, K. Fu, C. Jiang, X. Huang, W. C. Chan, and T. McKeithan, “The combination of 2-DG and metformin inhibits the mTORC1 pathway and suppresses aggressive B cell lymphoma growth and survival,” Blood, vol. 122, 2013.
View at: Google Scholar
J. Zhu, Y. Zheng, H. Zhang, and H. Sun, “Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose regulates apoptosis in ovarian cancer cells via p38 MAPK/JNK signaling pathway,” American Journal of Translational Research, vol. 8, no. 11, pp. 4812–4821, 2016.
View at: Google Scholar
E. H. Kim, J.-H. Lee, Y. Oh et al., “Inhibition of glioblastoma tumorspheres by combined treatment with 2-deoxyglucose and metformin,” Neuro-Oncology, vol. 19, no. 2, pp. 197–207, 2017.
View at: Publisher Site | Google Scholar
V. Valera, M. J. Ferretti, D. D. Prabharasuth et al., “Is targeting glycolysis with 2-deoxyglucose a viable therapeutic approach to bladder cancer?” International Journal of Cancer Therapy and Oncology, vol. 5, p. 511, 2017.
View at: Google Scholar
A. Jalota, M. Kumar, B. C. Das, A. K. Yadav, K. Chosdol, and S. Sinha, “Synergistic increase in efficacy of a combination of 2-deoxy-d-glucose and cisplatin in normoxia and hypoxia: switch from autophagy to apoptosis,” Tumor Biology, vol. 37, no. 9, pp. 12347–12358, 2016.
View at: Publisher Site | Google Scholar
A. L. Simons, I. M. Ahmad, D. M. Mattson, K. J. Dornfeld, and D. R. Spitz, “2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells,” Cancer Research, vol. 67, no. 7, pp. 3364–3370, 2007.
View at: Publisher Site | Google Scholar
S.-Y. Wang, Y.-H. Wei, D.-B. Shieh et al., “2-Deoxy-D-glucose can complement doxorubicin and sorafenib to suppress the growth of papillary thyroid carcinoma cells,” PLoS One, vol. 10, no. 7, 2015.
View at: Publisher Site | Google Scholar
I. M. Ahmad, E. H. Mustafa, N. H. Mustafa, L. H. Tahtamouni, and M. Y. Abdalla, “2DG enhances the susceptibility of breast cancer cells to doxorubicin,” Central European Journal of Biology, vol. 5, no. 6, pp. 739–748, 2010.
View at: Publisher Site | Google Scholar
E. H. Mustafa, “2-deoxy-D-glucose synergizes with doxorubicin or L-buthionine sulfoximine to reduce adhesion and migration of breast cancer cells,” Asian Pacific Journal of Cancer Prevention, vol. 16, no. 8, pp. 3213–3222, 2015.
View at: Publisher Site | Google Scholar
B. S. Pattni, A. Jhaveri, I. Dutta, J. D. Baleja, A. Degterev, and V. Torchilin, “Targeting energy metabolism of cancer cells: combined administration of NCL-240 and 2-DG,” International Journal of Pharmacy, vol. 532, no. 1, pp. 149–156, 2017.
View at: Publisher Site | Google Scholar
X. Cao, L. Fang, S. Gibbs et al., “Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia,” Cancer Chemotherapy and Pharmacology, vol. 59, no. 4, pp. 495–505, 2007.
View at: Publisher Site | Google Scholar
H. Liu, “Combining 2-deoxy-D-glucose with fenofibrate leads to tumor cell death mediated by simultaneous induction of energy and ER stress,” Oncotarget, vol. 7, no. 24, pp. 36461–36473, 2016.
View at: Publisher Site | Google Scholar
G. Cheng, J. Zielonka, B. P. Dranka et al., “Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death,” Cancer Research, vol. 72, no. 10, pp. 2634–2644, 2012.
View at: Publisher Site | Google Scholar
Y. Zhao, H. Liu, Z. Liu et al., “Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism,” Cancer Research, vol. 71, no. 13, pp. 4585–4597, 2011.
View at: Publisher Site | Google Scholar
R. L. Aft, F. W. Zhang, and D. Gius, “Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death,” British Journal of Cancer, vol. 87, no. 7, pp. 805–812, 2002.
View at: Publisher Site | Google Scholar
C. Rae, C. H. C. Sey, and R. J. Mairs, “Radiosensitization of prostate cancer cells by 2-deoxy-d-glucose,” Madridge Journal of Oncogenesis, vol. 2, pp. 30–34, 2018.
View at: Google Scholar
A. M. Al-Shammari, A. H. Abdullah, Z. M. Allami, and N. Y. Yaseen, “2-deoxyglucose and newcastle disease virus synergize to kill breast cancer cells by inhibition of glycolysis pathway through glyceraldehyde3-phosphate downregulation,” Frontiers in Molecular Biosciences, vol. 6, 2019.
View at: Publisher Site | Google Scholar
X. Lei, K. Li, Y. Liu et al., “Co-delivery nanocarriers targeting folate receptor and encapsulating 2-deoxyglucose and α-tocopheryl succinate enhance anti-tumor effect in vivo,” International Journal of Nanomedicine, vol. 12, pp. 5701–5715, 2017.
View at: Publisher Site | Google Scholar
S. Gupta, R. Mathur, and B. S. Dwarakanath, “The glycolytic inhibitor 2-deoxy-D-glucose enhances the efficacy of etoposide in Ehrlich ascites tumor-bearing mice,” Cancer Biology & Therapy, vol. 4, no. 1, pp. 94–101, 2005.
View at: Publisher Site | Google Scholar
C. Gao, Y. Shen, F. Jin, Y. Miao, and X. Qiu, “Cancer stem cells in small cell lung cancer cell line H446: higher dependency on oxidative phosphorylation and mitochondrial substrate-level phosphorylation than non-stem cancer cells,” PLoS One, vol. 11, no. 5, 2016.
View at: Publisher Site | Google Scholar
C. R. Kennedy, S. B. Tilkens, H. Guan, J. A. Garner, P. M. Y. Or, and A. M. Chan, “Differential sensitivities of glioblastoma cell lines towards metabolic and signaling pathway inhibitions,” Cancer Letters, vol. 336, no. 2, pp. 299–306, 2013.
View at: Publisher Site | Google Scholar
V. Miranda-Gonçalves, D. Cardoso-Carneiro, I. Valbom et al., “Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells,” Oncotarget, vol. 8, no. 61, pp. 103657–103670, 2017.
View at: Publisher Site | Google Scholar
R. Reyes, N. A. Wani, K. Ghoshal, S. T. Jacob, and T. Motiwala, “Sorafenib and 2-deoxyglucose synergistically inhibit proliferation of both sorafenib-sensitive and -resistant HCC cells by inhibiting ATP production,” Gene Expression, vol. 17, no. 2, pp. 129–140, 2017.
View at: Publisher Site | Google Scholar
M. Tomizawa, F. Shinozaki, Y. Motoyoshi, T. Sugiyama, S. Yamamoto, and N. Ishige, “2-Deoxyglucose and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells,” Oncology Letters, vol. 13, no. 2, pp. 800–804, 2017.
View at: Publisher Site | Google Scholar
Z. Zhelev, D. Ivanova, I. Aoki, T. Saga, and R. Bakalova, “2-Deoxy-D-glucose sensitizes cancer cells to barasertib and Everolimus by ROS-independent mechanism(s),” Anticancer Research, vol. 35, no. 12, pp. 6623–6632, 2015.
View at: Google Scholar
L.-X. Fan, C.-M. Liu, A.-H. Gao, Y.-B. Zhou, and J. Li, “Berberine combined with 2-deoxy-d-glucose synergistically enhances cancer cell proliferation inhibition via energy depletion and unfolded protein response disruption,” Biochimica et Biophysica Acta, General Subjects, vol. 1830, no. 11, pp. 5175–5183, 2013.
View at: Publisher Site | Google Scholar
D. Grahame Hardie, “Regulation of AMP-activated protein kinase by natural and synthetic activators,” Acta Pharmaceutica Sinica B, vol. 6, no. 1, pp. 1–19, 2016.
View at: Publisher Site | Google Scholar
Y.-Y. Pang, T. Wang, F.-Y. Chen et al., “Glycolytic inhibitor 2-deoxy-d-glucose suppresses cell proliferation and enhances methylprednisolone sensitivity in non-Hodgkin lymphoma cells through down-regulation of HIF-1α and c-MYC,” Leukemia and Lymphoma, vol. 56, no. 6, pp. 1821–1830, 2015.
View at: Publisher Site | Google Scholar
G. Maschek, N. Savaraj, W. Priebe et al., “2-Deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo,” Cancer Research, vol. 64, no. 1, pp. 31–34, 2004.
View at: Publisher Site | Google Scholar
S. M. Kim, M. R. Yun, Y. K. Hong et al., “Glycolysis inhibition sensitizes non-small cell lung cancer with T790M mutation to irreversible EGFR inhibitors via translational suppression of Mcl-1 by AMPK activation,” Molecular Cancer Therapeutics, vol. 12, no. 10, pp. 2145–2156, 2013.
View at: Publisher Site | Google Scholar
B. V Reddy and N. R. Prasad, “2-deoxy-D-glucose combined with ferulic acid enhances radiation response in non-small cell lung carcinoma cells,” Central European Journal of Biology, vol. 6, no. 5, pp. 743–755, 2011.
View at: Publisher Site | Google Scholar
L. Goldberg, R. Israeli, and Y. Kloog, “FTS and 2-DG induce pancreatic cancer cell death and tumor shrinkage in mice,” Cell Death & Disease, vol. 3, no. 3, 2012.
View at: Publisher Site | Google Scholar
Y. Cheng, D. Diao, H. Zhang et al., “High glucose-induced resistance to 5-fluorouracil in pancreatic cancer cells alleviated by 2-deoxy-D-glucose,” Biomedical Reports, vol. 2, pp. 188–192, 2014.
View at: Google Scholar
M. Chiaravalli, I. Rowe, V. Mannella et al., “2-Deoxy-d-Glucose ameliorates PKD progression,” Journal of the American Society of Nephrology, vol. 27, no. 7, pp. 1958–1969, 2016.
View at: Publisher Site | Google Scholar
J. M. Rho, L.-R. Shao, and C. E. Stafstrom, “2-Deoxyglucose and beta-hydroxybutyrate: metabolic agents for seizure control,” Frontiers in Cellular Neuroscience, vol. 13, 2019.
View at: Publisher Site | Google Scholar
X. Lian, X. Wu, Z. Li et al., “The combination of metformin and 2-deoxyglucose significantly inhibits cyst formation in miniature pigs with polycystic kidney disease,” British Journal of Pharmacology, vol. 176, no. 5, pp. 711–724, 2019.
View at: Publisher Site | Google Scholar
J. Zhao, Y. Ma, Y. Zhang et al., “Low-dose 2-deoxyglucose and metformin synergically inhibit proliferation of human polycystic kidney cells by modulating glucose metabolism,” Cell Death Discovery, vol. 5, p. 76, 2019.
View at: Publisher Site | Google Scholar
J. H. Cheong, E. S. Park, J. Liang et al., “Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models,” Molecular Cancer Therapeutics, vol. 10, no. 12, pp. 2350–2362, 2011.
View at: Publisher Site | Google Scholar
S. H. Cha, M. Wolfgang, Y. Tokutake, S. Chohnan, and M. D. Lane, “Differential effects of central fructose and glucose on hypothalamic malonyl-CoA and food intake,” Proceedings of the National Academy of Sciences, vol. 105, no. 44, pp. 16871–16875, 2008.
View at: Publisher Site | Google Scholar
I. Bady, N. Marty, M. Dallaporta et al., “Evidence from glut2-null mice that glucose is a critical physiological regulator of feeding,” Diabetes, vol. 55, no. 4, pp. 988–995, 2006.
View at: Publisher Site | Google Scholar
J. A. Gonzalez, L. T. Jensen, L. Fugger, and D. Burdakov, “Metabolism-independent sugar sensing in central orexin neurons,” Diabetes, vol. 57, no. 10, pp. 2569–2576, 2008.
View at: Publisher Site | Google Scholar
J. A. Chalmers, J. J. Jang, and D. D. Belsham, “Glucose sensing mechanisms in hypothalamic cell models: glucose inhibition of AgRP synthesis and secretion,” Molecular and Cellular Endocrinology, vol. 382, no. 1, pp. 262–270, 2014.
View at: Publisher Site | Google Scholar
J. DeSalvo, J. N. Kuznetsov, J. Du et al., “Inhibition of Akt potentiates 2-DG - induced apoptosis via downregulation of UPR in acute lymphoblastic leukemia,” Molecular Cancer Research, vol. 10, no. 7, 2012.
View at: Publisher Site | Google Scholar
S. Singh, S. Pandey, A. S. Chawla et al., “Dietary 2-deoxy-D-glucose impairs tumour growth and metastasis by inhibiting angiogenesis,” European Journal of Cancer, vol. 123, pp. 11–24, 2019.
View at: Publisher Site | Google Scholar
H. R. MacDonald, “Energy metabolism and T-cell-mediated cytolysis. II. Selective inhibition of cytolysis by 2-deoxy-D-glucose,” Journal of Experimental Medicine, vol. 146, no. 3, pp. 710–719, 1977.
View at: Publisher Site | Google Scholar
M. Vendrell, A. Samanta, S. W. Yun, and Y. T. Chang, “Synthesis and characterization of a cell-permeable near-infrared fluorescent deoxyglucose analogue for cancer cell imaging,” Organic and Biomolecular Chemistry, vol. 9, no. 13, pp. 4760–4762, 2011.
View at: Publisher Site | Google Scholar
A. I. Kuzmin, V. M. Pogorelov, D. V. Zaretsky, O. S. Medvedev, and E. I. Chazov, “Comparison of the effects of 2-deoxyglucose and immobilization on secretion and synthesis rate of catecholamines in the adrenal gland: a microdialysis study in conscious rats,” Acta Physiologica Scandinavica, vol. 155, no. 2, pp. 147–155, 1995.
View at: Publisher Site | Google Scholar
P. J. Little, K. D. Drennon, and L. R. Tannock, “Glucosamine inhibits the synthesis of glycosaminoglycan chains on vascular smooth muscle cell proteoglycans by depletion of ATP,” Archives of Physiology and Biochemistry, vol. 114, no. 2, pp. 120–126, 2008.
View at: Publisher Site | Google Scholar
D. B. MacLean, “Substance P synthesis and transport in explants of nodose ganglion/vagus nerve: effects of double ligation, 2-deoxyglucose, veratridine, and ouabain,” Journal of Neurochemistry, vol. 48, no. 6, pp. 1794–1803, 1987.
View at: Publisher Site | Google Scholar
S. C. Kuo and J. O. Lampen, “Inhibition by 2-deoxy-D-glucose of synthesis of glycoprotein enzymes by protoplasts of Saccharomyces: relation to inhibition of sugar uptake and metabolism,” Journal of Bacteriology, vol. 111, no. 2, pp. 419–429, 1972.
View at: Publisher Site | Google Scholar
V. Farkaš, A. Svoboda, and Š. Bauer, “Secretion of cell-wall glycoproteins by yeast protoplasts. Effect of 2-deoxy-d-glucose and cycloheximide,” Biochemical Journal, vol. 118, no. 5, pp. 755–758, 1970.
View at: Publisher Site | Google Scholar
P. Liras and S. GascÓN, “Biosynthesis and secretion of yeast invertase: effect of cycloheximide and 2‐Deoxy‐d‐glucose,” European Journal of Biochemistry, vol. 23, no. 1, pp. 160–165, 1971.
View at: Publisher Site | Google Scholar
G. E. Woodward and F. B. Cramer, “2-Desoxyl-D-glucose as an inhibitor of anaerobic glycolysis in tumor tissue,” Journal of the Franklin Institute, vol. 254, no. 3, pp. 259-260, 1952.
View at: Publisher Site | Google Scholar
V. K. Jain, G. W. Höltz, W. Pohlit, and S. C. Purohit, “Inhibition of unscheduled DNA synthesis and repair of potentially lethal X-ray damage by 2-deoxy-D-glucose in yeast,” International Journal of Radiation Biology & Related Studies in Physics, Chemistry & Medicine, vol. 32, no. 2, pp. 175–180, 1977.
View at: Publisher Site | Google Scholar
V. K. Jain and W. Pohlit, “Influence of energy metabolism on the repair of X-ray damage in living cells,” Biophysik, vol. 8, no. 3, pp. 254–263, 1972.
View at: Publisher Site | Google Scholar
V. K. Jain, W. Pohlit, and S. C. Purohit, “Influence of energy metabolism on the repair of X-ray damage in living cells,” Radiation and Environmental Biophysics, vol. 12, no. 4, pp. 315–320, 1975.
View at: Publisher Site | Google Scholar
X. Hu, Q. Xu, H. Wan et al., “PI3K-Akt-mTOR/PFKFB3 pathway mediated lung fi broblast aerobic glycolysis and collagen synthesis in lipopolysaccharide-induced pulmonary fi brosis,” Laboratory Investigation, vol. 3, 2020.
View at: Publisher Site | Google Scholar
T. Suginohara, K. Wakabayashi, S. Ato, and R. Ogasawara, “l Pre of,” Metabolism, vol. 114, Article ID 154419, 2020.
View at: Publisher Site | Google Scholar
Y. Long, K. Zhuang, Z. Ji et al., “2-Deoxy-d-Glucose exhibits anti-seizure effects by mediating the netrin-G1-KATP signaling pathway in epilepsy,” Neurochemical Research, vol. 44, no. 4, pp. 994–1004, 2019.
View at: Publisher Site | Google Scholar
H. Yang, R. Guo, J. Wu et al., “The antiepileptic effect of the glycolytic inhibitor 2-Deoxy-d-Glucose is mediated by upregulation of KATP channel subunits Kir6.1 and Kir6.2,” Neurochemical Research, vol. 38, no. 4, pp. 677–685, 2013.
View at: Publisher Site | Google Scholar
L. Shao, J. M. Rho, and C. E. Stafstrom, “Glycolytic inhibition: a novel approach toward controlling neuronal excitability and seizures,” Epilepsia Open, vol. 3, no. 2, pp. 191–197, 2018.
View at: Publisher Site | Google Scholar
F. Cendes, W. H. Theodore, B. H. Brinkmann, V. Sulc, and G. D. Cascino, “Neuroimaging of Epilepsy,” Handbook of Clinical Neurology, vol. 136, pp. 985–1014, 2016.
View at: Publisher Site | Google Scholar
G. E. Parris, “2-Deoxy-d-glucose as a potential drug against fusogenic viruses including HIV,” Medical Hypotheses, vol. 70, no. 4, pp. 776–782, 2008.
View at: Publisher Site | Google Scholar
Y. Wang, J. Li, M. Sun et al., “Triggering unfolded protein response by 2-Deoxy-d-glucose inhibits porcine epidemic diarrhea virus propagation,” Antiviral Research, vol. 106, pp. 33–41, 2014.
View at: Publisher Site | Google Scholar
L. Wali, M. Karbiener, S. Chou et al., “Host-directed therapy with 2-deoxy-D-glucose inhibits human rhinoviruses, endemic coronaviruses, and SARS-CoV-2,” Journal of Virus Eradication, vol. 8, no. 4, Article ID 100305, 2022.
View at: Publisher Site | Google Scholar
K. C. Samal, B. Panda, and L. Behera, “Anti-Covid Drug: 2-deoxy- D-Glucose and its Mechanism of Action,” Master and Doctoral Programme, vol. 3, no. 5, pp. 345–347, 2021.
View at: Google Scholar
V. Malgotra and V. Sharma, “2-Deoxy-d-glucose Inhibits Replication of Novel Coronavirus (SARS-CoV-2) with Adverse Effects on Host Cell Metabolism,” Medicine & Pharmacology, pp. 1–20, 2021.
View at: Publisher Site | Google Scholar
E. A. Mesri and T. J. Lampidis, “2-Deoxy-d-glucose exploits increased glucose metabolism in cancer and viral-infected cells: relevance to its use in India against SARS-CoV-2,” IUBMB Life, vol. 73, no. 10, pp. 1198–1204, 2021.
View at: Publisher Site | Google Scholar
A. N. Bhatt, S. Shenoy, S. Munjal et al., “2-deoxy-d-glucose as an adjunct to standard of care in the medical management of COVID-19: a proof-of-concept and dose-ranging randomised phase II clinical trial,” BMC Infectious Diseases, vol. 22, no. 1, 2022.
View at: Publisher Site | Google Scholar
K. Vivekanandhan, P. Shanmugam, H. Barabadi et al., “Emerging therapeutic approaches to combat COVID-19: present status and future perspectives,” Frontiers in Molecular Biosciences, vol. 8, 2021.
View at: Publisher Site | Google Scholar
C. Watanabe, Y. Okiyama, S. Tanaka, K. Fukuzawa, and T. Honma, “Molecular recognition of SARS-CoV-2 spike glycoprotein: quantum chemical hot spot and epitope analyses,” Chemical Science, vol. 12, no. 13, pp. 4722–4739, 2021.
View at: Publisher Site | Google Scholar
A. Balkrishna, P. Thakur, S. Singh, S. Dev, V. Jain, and R. Sharma, “Glucose antimetabolite 2-Deoxy-D-Glucose and its derivative as promising candidates for tackling COVID-19: insights derived from in silico docking and molecular simulations,” Authorea, 2021.
View at: Publisher Site | Google Scholar
L. S. Eibschutz, B. Rabiee, S. Asadollahi et al., “FDG-PET/CT of COVID-19 and other lung infections,” Seminars in Nuclear Medicine, vol. 52, no. 1, pp. 61–70, 2022.
View at: Publisher Site | Google Scholar
M. Ferreira, P. Lovinfosse, J. Hermesse et al., “[18F]FDG PET radiomics to predict disease-free survival in cervical cancer: a multi-scanner/center study with external validation,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 48, no. 11, pp. 3432–3443, 2021.
View at: Publisher Site | Google Scholar
G. Venkatesh, Y. Sixto-López, P. Vennila et al., “An investigation on the molecular structure, interaction with metal clusters, anti-Covid-19 ability of 2-deoxy-D-glucose: DFT calculations, MD and docking simulations,” Journal of Molecular Structure, vol. 1258, 2022.
View at: Publisher Site | Google Scholar
A. Gupta, S. S. Chauhan, A. S. Gaur, and R. Parthasarathi, “Computational screening for investigating the synergistic regulatory potential of drugs and phytochemicals in combination with 2-deoxy-D-glucose against SARS-CoV-2,” Structural Chemistry, vol. 33, no. 6, pp. 2179–2193, 2022.
View at: Publisher Site | Google Scholar
A. Fadaka, B. Ajiboye, O. Ojo, O. Adewale, I. Olayide, and R. Emuowhochere, “Biology of glucose metabolization in cancer cells,” Journal of Oncological Sciences, vol. 3, no. 2, pp. 45–51, 2017.
View at: Publisher Site | Google Scholar
A. Goel and S. Shah, “Hyperglycemia: an independent accompaniment of COVID -19,” Journal of Family Medicine and Primary Care, vol. 10, no. 1, p. 583, 2021.
View at: Publisher Site | Google Scholar
A. C. Codo, “Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1α/Glycolysis-Dependent Axis,” Cell Metabolism, vol. 32, no. 3, pp. 498-499, 2020.
View at: Publisher Site | Google Scholar
X. D. Zhang, E. Deslandes, M. Villedieu et al., “Effect of 2-deoxy-D-glucose on various malignant cell lines in vitro,” Anticancer Research, vol. 26, no. 5A, pp. 3561–3566, 2006.
View at: Google Scholar
J. Zhu, G. Wang, X. Huang et al., “SARS-CoV-2 Nsp6 damages Drosophila heart and mouse cardiomyocytes through MGA/MAX complex-mediated increased glycolysis,” Communications Biology, vol. 5, no. 1, 1039 pages, 2022.
View at: Publisher Site | Google Scholar
R. Thirumalaisamy, V. Aroulmoji, R. Khan et al., “SARS-CoV-2 Nsp6 damages Drosophila heart and mouse cardiomyocytes through MGA/MAX complex-mediated increased glycolysis,” Communications Biology, vol. 5, no. 1, 1039 pages, 2022.
View at: Publisher Site | Google Scholar
D. Bojkova, K. Klann, B. Koch et al., “Proteomics of SARS-CoV-2-infected host cells reveals therapy targets,” Nature, vol. 583, no. 7816, pp. 469–472, 2020.
View at: Publisher Site | Google Scholar
A. Vishwanatha, C. Rallis, S. Bevkal Subramanyaswamy, C. J. M. D’Souza, J. Bähler, and M. E. Schweingruber, “Identification of nuclear genes affecting 2-Deoxyglucose resistance in Schizosaccharomyces pombe,” FEMS Yeast Research, vol. 16, no. 6, 2016.
View at: Publisher Site | Google Scholar
A. Verma, A. Adhikary, G. Woloschak, B. S. Dwarakanath, and R. V. L. Papineni, “A combinatorial approach of a polypharmacological adjuvant 2-deoxy-D-glucose with low dose radiation therapy to quell the cytokine storm in COVID-19 management,” International Journal of Radiation Biology, vol. 96, no. 11, pp. 1323–1328, 2020.
View at: Publisher Site | Google Scholar
B. bu Kang and B. huang Chiang, “A novel phenolic formulation for treating hepatic and peripheral insulin resistance by regulating GLUT4-mediated glucose uptake,” Journal of Traditional and Complementary Medicine, vol. 12, no. 2, pp. 195–205, 2022.
View at: Publisher Site | Google Scholar
L. Sokoloff, M. Reivich, C. Kennedy et al., “The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat,” Journal of Neurochemistry, vol. 28, no. 5, pp. 897–916, 1977.
View at: Publisher Site | Google Scholar
M. Kilintari, V. Raos, and H. E. Savaki, “Grasping in the dark activates early visual cortices,” Cerebral Cortex, vol. 21, no. 4, pp. 949–963, 2011.
View at: Publisher Site | Google Scholar
M. E. Phelps, S. C. Huang, E. J. Hoffman, C. Selin, L. Sokoloff, and D. E. Kuhl, “Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method,” Annals of Neurology, vol. 6, no. 5, pp. 371–388, 1979.
View at: Publisher Site | Google Scholar
L. J. Brown, D. R. Bouvet, S. Champion et al., “A solid-phase route to 18F-labeled tracers, exemplified by the synthesis of [18F]2-fluoro-2-deoxy-D-glucose,” Angewandte Chemie International Edition, vol. 46, no. 6, pp. 941–944, 2007.
View at: Publisher Site | Google Scholar
S. Panareo, L. Urso, A. Nieri et al., “Clinical-diagnostic relevance of breast ‘incidentaloma’ detected during 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography: correlation with radiological imaging and histopathology,” Indian Journal of Nuclear Medicine, vol. 36, no. 4, pp. 385–390, 2021.
View at: Publisher Site | Google Scholar
A. Canosa, A. Martino, U. Manera et al., “Role of brain 2-[18F]fluoro-2-deoxy-D-glucose-positron-emission tomography as survival predictor in amyotrophic lateral sclerosis,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 50, no. 3, pp. 784–791, 2022.
View at: Publisher Site | Google Scholar
M. S. A. Fraz, N. Moe, M. E. Revheim et al., “Granulomatous-lymphocytic interstitial lung disease in common variable immunodeficiency—features of CT and 18F-FDG positron emission tomography/CT in clinically progressive disease,” Frontiers in Immunology, vol. 11, 2021.
View at: Publisher Site | Google Scholar
O. Cohen, M. M. John, A. E. Kaufman et al., “Novel non-invasive assessment of upper airway inflammation in obstructive sleep apnea using positron emission tomography/magnetic resonance imaging,” Sleep and Breathing, vol. 26, no. 3, pp. 1087–1096, 2022.
View at: Publisher Site | Google Scholar
M. Zanello, E. Bozier, and J. Pallud, “Positron emission tomography scan: a good way to untie the gordian knot of infection in case of multiple ventriculoperitoneal shunts,” World Neurosurg, vol. 159, pp. 144-145, 2022.
View at: Publisher Site | Google Scholar
K. Ozierański, A. Tymińska, M. Kobylecka et al., “Positron emission tomography in clinically suspected myocarditis – STREAM study design,” International Journal of Cardiology, vol. 332, pp. 113–118, 2021.
View at: Publisher Site | Google Scholar
A. Aydh, M. Abufaraj, K. Mori et al., “Performance of fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography imaging for lymph node staging in bladder and upper tract urothelial carcinoma: a systematic review,” Arab Journal of Urology, vol. 19, no. 1, pp. 59–66, 2021.
View at: Publisher Site | Google Scholar
H. J. A. Adams, R. A. J. Nievelstein, and T. C. Kwee, “Systematic review on the additional value of 18F-Fluoro-2-Deoxy-D-Glucose positron emission tomography in staging follicular lymphoma,” Journal of Computer Assisted Tomography, vol. 41, no. 1, pp. 98–103, 2017.
View at: Publisher Site | Google Scholar
K. S. M. Van der Geest, G. Treglia, A. W. J. M. Glaudemans et al., “Diagnostic value of [18F]FDG-PET/CT in polymyalgia rheumatica: a systematic review and meta-analysis,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 48, no. 6, pp. 1876–1889, 2021.
View at: Publisher Site | Google Scholar
C. Sakulpisuti, P. Charoenphun, and W. Chamroonrat, “Positron emission tomography radiopharmaceuticals in differentiated thyroid cancer,” Molecules, vol. 27, no. 15, 2022.
View at: Publisher Site | Google Scholar
D. Vriens, J. H. W. de Wilt, G. J. van der Wilt, R. T. Netea-Maier, W. J. G. Oyen, and L. F. de Geus-Oei, “The role of [ 18 F]-2-fluoro-2-deoxy-d-glucose-positron emission tomography in thyroid nodules with indeterminate fine-needle aspiration biopsy,” Cancer, vol. 117, no. 20, pp. 4582–4594, 2011.
View at: Publisher Site | Google Scholar
E. J. De Koster, O. Husson, E. W. C. M. van Dam et al., “Health-related quality of life following FDG-PET/CT for cytological indeterminate thyroid nodules,” Endocrine Connections, vol. 11, no. 8, 2022.
View at: Publisher Site | Google Scholar
R. w. Binkley and D. Bankaitis, “Photochemically based synthesis of deoxy sugars. Synthesis of 2-deoxy- D - arabino -hexopyranose (2-deoxy- D -glucose) and several of its derivatives from 3,4,6-tri- O -acetyl- D -glucal,” Journal of Carbohydrate Chemistry, vol. 1, no. 1, pp. 1–8, 1982.
View at: Publisher Site | Google Scholar
C. H. Marzabadi and R. W. Franck, “The synthesis of 2-deoxyglycosides: 1988-1999,” Tetrahedron, vol. 56, no. 43, pp. 8385–8417, 2000.
View at: Publisher Site | Google Scholar
M. Koóš, “An alternative route to 2-deoxysugar and 2,3-unsaturated sugar derivatives via the corresponding 1-nitro-1-alkenes,” Tetrahedron Letters, vol. 41, no. 28, pp. 5403–5406, 2000.
View at: Publisher Site | Google Scholar
J. S. Yadav, B. V. S. Reddy, K. B. Reddy, and M. Satyanarayana, “CeCl3·7H2O: a novel reagent for the synthesis of 2-deoxysugars from d-glycals,” Tetrahedron Letters, vol. 43, no. 39, pp. 7009–7012, 2002.
View at: Publisher Site | Google Scholar
B. Pająk, R. Zieliński, J. T. Manning et al., “The antiviral effects of 2-Deoxy-D-glucose (2-DG), a dual D-glucose and D-mannose mimetic, against SARS-CoV-2 and other highly pathogenic viruses,” Molecules, vol. 27, no. 18, 5928 pages, 2022.
View at: Publisher Site | Google Scholar
Y. Masuda, H. Tsuda, and M. Murakami, “C1 oxidation/C2 reduction isomerization of unprotected aldoses induced by light/ketone,” Angewandte Chemie International Edition, vol. 59, no. 7, pp. 2755–2759, 2020.
View at: Publisher Site | Google Scholar
W. R. Roush, J. A. Straub, and M. S. VanNieuwenhze, “A stereochemically general synthesis of 2-deoxyhexoses via the asymmetric allylboration of 2,3-epoxy aldehydes,” Journal of Organic Chemistry, vol. 56, no. 4, pp. 1636–1648, 1991.
View at: Publisher Site | Google Scholar
J. C. Sowden and H. O. L. Fischer, “Carbohydrate C-nitroalcohols: the acetylated nitroölefins,” Journal of the American Chemical Society, vol. 69, no. 5, pp. 1048–1050, 1947.
View at: Publisher Site | Google Scholar
C. W. Borysenko, A. Spaltenstein, J. A. Straub, and G. M. Whitesides, “The synthesis of aldose sugars from half-protected dialdehydes using rabbit muscle aldolase,” Journal of the American Chemical Society, vol. 111, no. 26, pp. 9275-9276, 1989.
View at: Publisher Site | Google Scholar
Y.-M. Kim, M. Okuyama, H. Mori et al., “Enzymatic synthesis of alkyl α-2-deoxyglucosides by alkyl alcohol resistant α-glucosidase from Aspergillus Niger,” Tetrahedron: Asymmetry, vol. 16, no. 2, pp. 403–409, 2005.
View at: Publisher Site | Google Scholar
V. P. Chavda, R. Pandya, and V. Apostolopoulos, “DNA vaccines for SARS-CoV-2: toward third-generation vaccination era,” Expert Review of Vaccines, vol. 20, no. 12, pp. 1549–1560, 2021.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2023 Raman Singh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

2133

Downloads

680

Citations